Clinical trials: psoriasis
Plaque Psoriasis
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
- Trial name
- NCT02134210
- Testing
- Etanercept, CHS-0214
- Where
- 100 sites in United States, Australia and 5 more
- Volunteers
- 521 people
- Sponsor
- Coherus Oncology, Inc.
Genital Psoriasis, Scalp Psoriasis
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques.
- Trial name
- UnlIMMited (NCT05969223)
- Testing
- Risankizumab
- Where
- 38 sites in United States
- Volunteers
- 214 people
- Sponsor
- AbbVie
Psoriasis
A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis
In recent years, biologics have changed the treatment of psoriasis, giving us additional therapeutic options that are potentially less toxic to the liver, kidneys, and bone marrow and are not teratogenic.
- Trial name
- NCT01126619
- Where
- 25 sites in Turkey (Türkiye)
- Volunteers
- 103 people
- Sponsor
- Abbott
Plaque Psoriasis
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Stable Plaque Psoriasis.
- Trial name
- NCT00733954
- Testing
- clobetasol propionate spray, clobetasol propionate ointment
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Galderma R&D
Palmoplantar Pustulosis
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
- Trial name
- NCT05710185
- Testing
- Deucravacitinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Brigham and Women's Hospital
Plaque Psoriasis
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
- Trial name
- NCT04128007
- Testing
- Roflumilast foam 0.3%, Vehicle foam
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 304 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis.
- Trial name
- NCT04053387
- Testing
- tapinarof cream, 1%
- Where
- 104 sites in United States, Canada
- Volunteers
- 763 people
- Sponsor
- Organon and Co
Psoriatic Arthritis
A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
The purpose of this study is to learn about the safety and effects of the study medicine for the potential treatment of Psoriatic Arthritis (PsA).
- Trial name
- NCT05195814
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Pfizer
Plaque Psoriasis
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
- Trial name
- SAIL (NCT04203693)
- Testing
- Tildrakizumab
- Where
- 41 sites in Austria, Belgium and 4 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Psoriatic Arthritis (PsA)
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE2 (NCT03671148)
- Testing
- Risankizumab
- Where
- 138 sites in United States, Argentina and 23 more
- Volunteers
- 444 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
Safety and Efficacy of Combining nbUVB to Etanercept in Patients
This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.
- Trial name
- NCT00640393
- Testing
- Etanercept, nbUVB
- Where
- 10 sites in Canada
- Volunteers
- 99 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis Vulgaris
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
- Trial name
- NCT02038569
- Testing
- LEO 80185 gel
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- LEO Pharma
Psoriasis
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
- Trial name
- NCT00617994
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Plaque Psoriasis
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06176768
- Testing
- LY3972406
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Moderate to Severe Plaque Psoriasis With Scalp Involvement
The purpose of this study is to determine if etanercept is effective in the treatment of scalp involvement in moderate to severe plaque psoriasis.
- Trial name
- NCT00791765
- Testing
- Etanercept
- Volunteers
- 124 people
- Sponsor
- Amgen
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
- Trial name
- Ixora-peds (NCT03073200)
- Testing
- Ixekizumab, Etanercept
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Chronic Plaque Psoriasis
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult…
- Trial name
- DERMIS-1 (NCT04211363)
- Testing
- Roflumilast 0.3% cream, Vehicle Cream
- Where
- 40 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Plaque Psoriasis, Psoriasis
Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the…
- Trial name
- NCT03506477
- Testing
- Enstilar® foam, Vehicle foam
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Psoriasis Vulgaris
LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
- Trial name
- NCT02668692
- Testing
- LEO 80185 gel, Dovobet ® ointment
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- LEO Pharma